Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) is a leading biotechnology company based in Tarrytown, New York. REGN develops therapies for eye diseases, cancer, allergic conditions, and infectious diseases. Its portfolio contains commercial Eylea, Dupixent, and Libtayo that address critical medical needs andMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) were down 4.63% after an unfavorable ruling in its lawsuit against Amgen (AMGN) in the United States District Court for the Northern District of West Virginia.The lawsuit was related to a biosimilar of its lead drug Eylea (aflibercept 2 mg).Regeneron’s shares have rallied 24.3% year to date against the industry’s decline of 1.5%.Image Source: Zacks Investment ResearchREGN’s Lawsuit Against AMGNEylea, REGN’s lead drug, is approved for various retinal condition ...

文章核心观点 1. 新型体重管理药物正在快速发展,预计到2030年将产生超过1000亿美元的年销售额 [1][2] 2. 诺和诺德和安进两家公司即将在2024年前发布新一代体重管理药物的临床试验结果,这可能会推动这些制药股价大涨 [2] 诺和诺德 1. 诺和诺德正在进行Redefine-1临床试验,测试一种新的组合疗法CagriSema(由cagrilintide和semaglutide组成) [3] 2. 在之前的II期试验中,CagriSema组的平均体重下降15.6%,远高于单独使用semaglutide的5.1% [3] 3. 如果Redefine-1试验结果能超过礼来公司tirzepatide的20.9%体重下降,诺和诺德股价可能会大涨 [4] 4. 但诺和诺德目前股价估值较高,市场已经预期CagriSema能取得超过21%的体重下降,这仍然存在不确定性 [4] 安进 1. 安进正在开发一种新的体重管理药物MariTide,它通过抑制GIP受体而非激活来发挥作用 [5][6] 2. 在I期试验中,最高剂量组患者平均体重下降14.5% [5] 3. MariTide还表现出了较长的体重维持效果,患者在最后一次注射150天后仍能保持体重下降 [5][6] 4. 安进正在进行II期试验,预计在2024年底前公布52周结果,如果结果良好,MariTide有望成为一款新的体重管理药物 [6] 5. 即使不考虑MariTide,安进目前的股价估值也不算高,加上其他多个增长迅速的重磅产品,未来发展前景看好 [6]

Amgen (AMGN) closed at $335.61 in the latest trading session, marking a -0.52% move from the prior day. This change lagged the S&P 500's daily gain of 0.28%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.15%.Shares of the world's largest biotech drugmaker witnessed a gain of 2.61% over the previous month, beating the performance of the Medical sector with its gain of 0.38% and the S&P 500's gain of 2%.Market participants will be closely following the financial results of Amgen in its ...

These two stocks could be rivals in the intense GLP-1 space in the future.Investing into companies involved with new weight loss medications can be overwhelming. There is a lot of competition in the space given the potential for the anti-obesity market to grow to a size of $100 billion or more, as per estimates from Goldman Sachs.The challenge becomes the following: Do you invest in an established healthcare company that is expanding into this new category of glucagon-like peptide-1 (GLP-1) medications, or ...

文章核心观点 - 公司最近一个交易日的股价下跌0.73%,低于标普500指数的涨幅0.03% [1] - 公司过去一个月内股价上涨2.22%,同期医疗行业上涨2.67%,标普500上涨1.54% [1] - 公司预计将在即将发布的财报中实现每股收益5.13美元,同比增长3.43%;预计收入将达到85.1亿美元,同比增长23.24% [1] - 对于全年业绩,分析师预计公司每股收益将达19.49美元,同比增长4.5%;收入将达332.1亿美元,同比增长17.82% [2] - 分析师对公司业绩预测有所下调,但公司目前仍维持中性评级 [3] - 公司估值水平相对行业平均水平有一定折价 [3] 行业和公司概况 - 公司是全球最大的生物制药公司 [1] - 公司所属医疗-生物医药和遗传学行业,在250多个行业中排名前32% [3] - 该行业过去一年平均市盈率为23.02倍,公司当前市盈率为17.2倍,折价明显 [3] - 该行业过去一年平均PEG率为2.28,公司当前PEG率为2.98 [3]

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor TypesTHOUSAND OAKS, Calif., Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona. The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecular ...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.If you want to invest in the fast-growing weight loss industry, going with stocks such as Eli Lilly or Novo Nordisk can seem like a great idea. They have leading weight loss products and possess some promising long-term growth opportunities. But they are already among the most valuable healthcare stocks in the world (their valuations are in excess of $ ...

Hispanolistic/E+ via Getty Images Investment Overview — Tango's Share Price Volatility Based On Competitor's Progress When I last covered Tango Therapeutics, Inc. (NASDAQ:TNGX) for Seeking Alpha, in January of this year, I gave the stock a “Buy” rating. I highlighted the fact that the Boston, Massachusetts-based biotech is one of only five companies to date — the others are Bristol Myers Squibb (BMY) (via its ~$5.8bn acquisition of Mirati Therapeutics), Amgen (AMGN), AstraZeneca (AZN), Johnson & Johnson ...

Central Press/Hulton Archive via Getty Images Written by Sam Kovacs Introduction Buy Low, Sell High, Get Paid To Wait. This is our investment philosophy. I make a point of repeating it as often as I can because it is so simple and elegant, that most investors overlook it. Einstein famously said that everything should be made as simple as possible, but not simpler. Well, this is as simple as it gets for investing. Of course, it brings up quite a few questions: what's low? What's high? Why get paid to wai ...